ImmunityBio, Inc. (IBRX)


+0.11 (+2.72%)
Symbol IBRX
Price $4.15
Beta -0.607
Volume Avg. 5.46M
Market Cap 2.771B
Shares () -
52 Week Range 1.21-7.1
1y Target Est -
DCF Unlevered IBRX DCF ->
DCF Levered IBRX LDCF ->
ROE 97.13% Strong Buy
ROA -114.00% Strong Sell
Operating Margin -
Debt / Equity -174.21% Sell
P/E -3.99 Strong Sell
P/B -5.02 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest IBRX news

Mr. Richard Gerald Adcock
NASDAQ Global Select

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.